VJHemOnc is committed to improving our service to you

EHA 2020 | Teclistamab for R/R myeloma

VJHemOnc is committed to improving our service to you

Maria-Victoria Mateos

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses a Phase I study of teclistamab, a humanized b-cell maturation antigen (BCMA), CD3 bispecific antibody, for the treatment of relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter